SCHEMBL19007909

SCHEMBL19007909

Cc1ccc(OCc2ccccc2)nc1C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
HTT P42858 2/20 0.47
PKM P14618 1/20 0.47
STAT3 P40763 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 1/20 0.46
FFAR1 O14842 1/20 0.44
NUDT1 P36639 1/20 0.44
NOX1 Q9Y5S8 1/20 0.44
GRM5 P41594 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
ATP4A P20648 1/20 0.41
ATP4B P51164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19273376 0.83 NUDT1 (0.49) L3MBTL1PKMSMN1; SMN2MAPTMAPK1
SCHEMBL19008193 0.83 PKM (0.45) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL30939981 0.83 PKM (0.49) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL23274021 0.83 NUDT1 (0.49) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL16805396 0.83 L3MBTL1 (0.49) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL24461271 0.83 PKM (0.45) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL15515593 0.83 PKM (0.49) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL24497447 0.83 PKM (0.45) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL25447293 0.80 LIPE (0.53) L3MBTL1HTTPKMSTAT3SMN1; SMN2
SCHEMBL26288734 0.80 HTT (0.47) L3MBTL1HTTPKMSTAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348431-A1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORPORATION 2023-11-02 US disclosed
US-11739075-B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith CELGENE CORPORATION (US) 2023-08-29 US disclosed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348431-A1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CRBN, AR, ESRRA L3MBTL1 2237/4885HTT 1544/4885PKM 2778/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 L3MBTL1 279/4885HTT 441/4885PKM 2875/4885
US-11739075-B2 Cereblon binding compounds, compositions thereof, and methods of treatment therewith CRBN, AR, ESRRA L3MBTL1 2237/4885HTT 1544/4885PKM 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.